Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2005
05/10/2005US6890735 TSG-like gene
05/10/2005US6890731 For drug screeing/therapy of diseases; bacteriophages
05/10/2005US6890721 For treating Alzheimer's/Parkinson's disease/rheumatoid arthritis/sepsis/stroke/inflammation/ischemia/cardiovascular/ liver disease/multiple sclerosis/acquired immune deficiency syndrome(AIDS)/male pattern baldness/tumors/cancer
05/10/2005US6890713 For improving the effectiveness of chemotherapy; drug screening/design
05/10/2005US6890710 For treating influenza infections in vivo; fusion proteins; solid phase synthesis
05/10/2005US6890709 For induction of S-phase/oncogenicity/transcription/apoptosis in cells
05/10/2005US6890554 Genetic immunization with cationic lipids
05/10/2005US6890552 Manufacturing therapeutic enclosures
05/10/2005US6890539 Peptide encoded by gene identified herein as pho2-2, obtainable from Group B Streptococcus, or a homologue or a functional fragment thereof; neonatal infections, urinary tract infections
05/10/2005US6890537 Antigrowth agents; microbiocides, bactericides
05/10/2005US6890536 Microsporidian polar tube proteins, nucleic acids coding for these proteins and their applications
05/10/2005US6890535 Pharmaceutical compositions and methods for treatment of amyloid diseases
05/10/2005US6890534 Aiolos genes and polypeptides of the present invention are useful for studying, diagnosing and/or treating diseases associated with unwanted cell proliferation, e.g., leukemias or lymphomas
05/10/2005US6890531 Neuronal growth factor galectin-1
05/10/2005US6890529 Edible foods, functional products or pharmaceuticals; nutraceutical; beverages
05/10/2005US6890523 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarreah agents
05/10/2005US6890518 Compositions of chemically modified insulin
05/10/2005US6890516 Identifying a substance capable of affecting long term memory in an animal comprising the determination that said substance alters activator homodimer, activator-repressor heterodimer and/ or repressor homodimer formation from normal
05/10/2005US6890339 Stent lining
05/10/2005CA2407562C Tryptophan source from plants and uses therefor
05/10/2005CA2363451C Oilseed processing
05/10/2005CA2330935C A mutant human hepatitis b viral strain and uses thereof
05/10/2005CA2279743C Pharmaceutical composition of hedgehog proteins and use thereof
05/10/2005CA2233009C Composition for improving pancreatic function
05/10/2005CA2222995C Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides
05/10/2005CA2116559C Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
05/10/2005CA2116192C Highly concentrated tcf pharmaceutical preparations
05/10/2005CA2111193C Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
05/10/2005CA2067330C Herpes simplex virus type 1 mutant
05/10/2005CA1341482C Process for preparing fragments of aids-associated retroviruses
05/06/2005WO2005040802A2 Cylin binding peptides, and their use in drug screening assays
05/06/2005WO2005040796A1 Modulators of ms4a gene products
05/06/2005WO2005040379A2 RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
05/06/2005WO2005040378A1 Nucleic acids useful for triggering tumor cell lethality
05/06/2005WO2005040375A1 A fungal immuromodulatory protein produced by microorganisme and uses thereof
05/06/2005WO2005040367A1 Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
05/06/2005WO2005040356A2 Mutant p53 protein and uses thereof
05/06/2005WO2005040351A2 Compositions for inducing cell growth and differentiation and methods of using same
05/06/2005WO2005040347A2 Methods and compositions for inhibiting cell growth and proliferation
05/06/2005WO2005040214A1 Virally-safe factor viii with a low content of higher multimers
05/06/2005WO2005040210A2 Novel cxcl8 antagonists
05/06/2005WO2005040209A1 Human chemokine hcc-1 polypeptides to improve stem cell transplantation
05/06/2005WO2005040208A2 Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
05/06/2005WO2005040207A1 Tyrosine phosphorylation of cdk inhibitor proteins of the cip/kip family
05/06/2005WO2005040205A1 Peptides with anti-obesity activity and other related uses
05/06/2005WO2005040204A1 A tumor-inhibiting protein and the use thereof
05/06/2005WO2005040201A1 Human cathelicidin antimicrobial peptides
05/06/2005WO2005040199A1 A bidentate motif and methods of use
05/06/2005WO2005040198A1 A binding motif and methods of regulating cell function
05/06/2005WO2005040195A2 Formulation of exendins
05/06/2005WO2005040192A2 Human cathelicidin antimicrobial peptides
05/06/2005WO2005040187A2 The use of sirna silencing in the prevention of metastasis
05/06/2005WO2005040180A2 Antisense modulation of superoxide dismutase 1, soluble (sod-1) expression
05/06/2005WO2005040142A1 Novel keto-oxadiazole derivatives as cathepsin inhibitors
05/06/2005WO2005039645A2 Sp1 and sp3 targeted cancer therapies and therapeutics
05/06/2005WO2005039644A1 Method of transferring soluble interferon ϝ receptor gene and composition for preventing or treating arteriosclerosis
05/06/2005WO2005039643A2 In vivo gene therapy of parkinson's disease
05/06/2005WO2005039642A1 Dna delivery with gemini cationic surfactants
05/06/2005WO2005039633A1 Agent for treating leishmania infections
05/06/2005WO2005039629A2 Caspase inhibitors as coating materiel for medical products for inhibiting restenosis
05/06/2005WO2005039628A1 Medicinal composition for treating/preventing diseases based on blood coagulation failure comprising blood coagulation factor x as the main ingredient
05/06/2005WO2005039627A2 Therapeutic applications for c-peptide
05/06/2005WO2005039626A2 Use of hydroxylated amino acids for treating diabetes
05/06/2005WO2005039625A1 Growth hormone secretagogue receptor agonists
05/06/2005WO2005039624A1 Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions
05/06/2005WO2005039623A1 Spray formulation for the treatment of viral infections
05/06/2005WO2005039622A2 Modulation of socs expression in the therapeutic regimens
05/06/2005WO2005039621A1 Fibroblast-mobilizing agent containing g-csf and wound remedy
05/06/2005WO2005039620A1 Stable aqueous g-csf-containing compositions
05/06/2005WO2005039619A1 Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia
05/06/2005WO2005039618A1 p185neu-ENCODING DNA AND THERAPEUTICAL USES THEREOF
05/06/2005WO2005039617A1 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof
05/06/2005WO2005039616A1 Angiogenic peptides and uses thereof
05/06/2005WO2005039615A1 Use of caspase-8 inhibitors for modulating hematopoiesis
05/06/2005WO2005039614A2 Omega interferon for the treatment of hiv/aids, cancer and human and veterinary asthma
05/06/2005WO2005039613A1 Lim2 inhibitor of lm02
05/06/2005WO2005039607A1 The use of balloonfish collagen i extractive in medical care and the preparative method of it
05/06/2005WO2005039603A1 Combined preparation for treating sepsis
05/06/2005WO2005039598A1 Method of treating alcoholic liver disease
05/06/2005WO2005039567A1 Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
05/06/2005WO2005039565A1 Combinations of cox and vasopressin inhibitors for the treatment of dismenorrhea
05/06/2005WO2005039530A1 Methods and compositions for treating erectile dysfunction
05/06/2005WO2005039498A2 Methods of treating cancer with hdac inhibitors
05/06/2005WO2005039495A2 Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
05/06/2005WO2005039485A2 Gsk-3 inhibitors and uses thereof
05/06/2005WO2005039318A1 Nutritional composition against side effects of chemotherapy of radiotherapy
05/06/2005WO2005030240A3 Vege-cor vege-d materials and methods for stimulation of neural stem cells
05/06/2005WO2005027895A3 Thyroid hormone analogs and methods of use in angiogenesis
05/06/2005WO2005025499A3 Hydrophobic drug compositions containing reconstitution enhancer
05/06/2005WO2005023834A3 Peptides and compounds that bind to thrombopoietin receptors
05/06/2005WO2005019448A3 NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
05/06/2005WO2004112482A8 Biological active coating components, coatings, and coated surfaces
05/06/2005WO2004104018A3 Compositions for delivering peptide yy and pyy agonists
05/06/2005WO2004091495A3 Compositions and methods related to production of erythropoietin
05/06/2005WO2004091487A3 Hemophilia treatment by inhalation of coagulation factors
05/06/2005WO2004091438B1 Improved ophthalmic and contact lens solutions containing peptides as representative enhancers
05/06/2005WO2004081533A3 Vault and vault-like carrier molecules
05/06/2005WO2004080418A3 Nucleic acid compounds for inhibiting angiogenesis and tumor growth
05/06/2005WO2004078949A3 Genes of an otitis media isolate of nontypeable haemophilus influenzae
05/06/2005WO2004078933A3 Intracellular delivery of small molecules proteins and nucleic acids
1 ... 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 ... 3163